These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25803908)

  • 1. [Effectiveness of continuous infusion of tizanidine (Ternelin) via a feeding tube for patients with the mixed type of tetraplegia].
    Hiejima I; Kumada T; Nozaki F; Hayasi A; Miyajima T; Fujii T
    No To Hattatsu; 2015 Jan; 47(1):28-31. PubMed ID: 25803908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
    Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
    Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia].
    Tanaka H; Fukuda I; Miyamoto A; Oka R; Cho K; Fujieda K
    No To Hattatsu; 2004 Nov; 36(6):455-60. PubMed ID: 15560387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sedative and sympatholytic effects of oral tizanidine in healthy volunteers.
    Miettinen TJ; Kanto JH; Salonen MA; Scheinin M
    Anesth Analg; 1996 Apr; 82(4):817-20. PubMed ID: 8615503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population.
    Smith HS; Barton AE
    Am J Hosp Palliat Care; 2000; 17(1):50-8. PubMed ID: 11094920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tizanidine withdrawal symptoms in stress cardiomyopathy].
    Mörkl S; Bengesser SA; Schöggl H; Bayer D; Kapfhammer HP
    Fortschr Neurol Psychiatr; 2015 Mar; 83(3):170-3. PubMed ID: 25794323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
    Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intrathecal baclofen in the treatment of severe spastic tetraplegia and dystonia in children and adolescents].
    Illum NO; Hansen FJ; Fischer C; Uldall PV; Nielsen OA
    Ugeskr Laeger; 2003 Apr; 165(17):1755-9. PubMed ID: 12768902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transdermal clonidine on spinal spasticity. A case series.
    Yablon SA; Sipski ML
    Am J Phys Med Rehabil; 1993 Jun; 72(3):154-7. PubMed ID: 8512678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia.
    Burns AS; Meythaler JM
    Spinal Cord; 2001 Aug; 39(8):413-9. PubMed ID: 11512071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
    Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
    Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
    Dai AI; Wasay M; Awan S
    J Child Neurol; 2008 Dec; 23(12):1464-6. PubMed ID: 19073853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified release tizanidine in the treatment of spasticity.
    Chantraine A; Van Ouwenaller C
    J Int Med Res; 1988; 16(6):459-65. PubMed ID: 3234596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life.
    Ivanhoe CB; Francisco GE; McGuire JR; Subramanian T; Grissom SP
    Arch Phys Med Rehabil; 2006 Nov; 87(11):1509-15. PubMed ID: 17084128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of orally administered tizanidine in healthy volunteers.
    Tse FL; Jaffe JM; Bhuta S
    Fundam Clin Pharmacol; 1987; 1(6):479-88. PubMed ID: 3447935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy.
    Meythaler JM; Guin-Renfroe S; Law C; Grabb P; Hadley MN
    Arch Phys Med Rehabil; 2001 Feb; 82(2):155-61. PubMed ID: 11239304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
    Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
    Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.